All In Biotech

Drug Trial Radar · NCT04490915

Global Safety and Efficacy Registration Study of Crinecerfont for Congenital Adrenal Hyperplasia

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Crinecerfont (NBI-74788) in Adult Subjects With Classic Congenital Adrenal Hyperplasia, Followed by Open-Label Treatment

Last checked: Nov 19, 2026Latest source record: May 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingPhase 3. Randomized with 182 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

182

Actual

Start

Dec 16, 2020

Primary completion

Jul 19, 2023

Study completion Aug 2027

Sponsor

Lead sponsor
Neurocrine BiosciencesNeurocrine Biosciences (NBIX)
Sponsor type
Industry
First posted
Jul 29, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 3 study to evaluate the efficacy, safety, and tolerability of crinecerfont versus placebo administered for 24 weeks in approximately 165 adult participants with classic CAH due to 21-hydroxylase deficiency. The study consists of a 24-week randomized, double-blind, placebo-controlled period, followed by 1 year of active treatment with crinecerfont. Subsequently, participants may elect to participate in the open-label extension (OLE) period. The duration of participation in the study is approximately 20 months for the core study and will be a variable amount of time per participant for the OLE (estimated to be approximately 3 years).

Conditions

  • Congenital Adrenal Hyperplasia

Interventions

  • CrinecerfontDrug

    CRF type 1 receptor antagonist

  • PlaceboDrug

    Non-active dosage form

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent Change From Baseline in Glucocorticoid Daily Dose at Week 24Time frame: Baseline, Week 24

Locations

70 sites in 18 countries. Site status is shown where the registry gives one.

  • Neurocrine Clinical Site

    Los Angeles, California

  • Neurocrine Clinical Site

    San Diego, California

  • Neurocrine Clinical Site

    San Francisco, California

  • Neurocrine Clinical Site

    Aurora, Colorado

  • Neurocrine Clinical Site

    Atlanta, Georgia

  • Neurocrine Clinical Site

    Indianapolis, Indiana

  • Neurocrine Clinical Site

    Bethesda, Maryland

  • Neurocrine Clinical Site

    Boston, Massachusetts

  • Neurocrine Clinical Site

    Ann Arbor, Michigan

  • Neurocrine Clinical Site

    Minneapolis, Minnesota

  • Neurocrine Clinical Site

    Rochester, Minnesota

  • Neurocrine Clinical Site

    St Louis, Missouri

  • Neurocrine Clinical Site

    Great Neck, New York

  • Neurocrine Clinical Site

    New York, New York

  • Neurocrine Clinical Site

    Winston-Salem, North Carolina

  • Neurocrine Clinical Site

    Tulsa, Oklahoma

  • Neurocrine Clinical Site

    Philadelphia, Pennsylvania

  • Neurocrine Clinical Site

    Pittsburgh, Pennsylvania

  • Neurocrine Clinical Site

    Dallas, Texas

  • Neurocrine Clinical Site

    Seattle, Washington

  • Neurocrine Clinical Site

    Graz, Austria

  • Neurocrine Clinical Site

    Vienna, Austria

  • Neurocrine Clinical Site

    Brussels, Belgium

  • Neurocrine Clinical Site

    Leuven, Belgium

  • Neurocrine Clinical Site

    Sofia, Bulgaria

  • Neurocrine Clinical Site

    Sofia, Bulgaria

  • Neurocrine Clinical Site

    Halifax, Nova Scotia, Canada

  • Neurocrine Clinical Site

    Hradec Králové, Czechia

  • Neurocrine Clinical Site

    Angers, France

  • Neurocrine Clinical Site

    Grenoble, France

  • Neurocrine Clinical Site

    Le Kremlin-Bicêtre, France

  • Neurocrine Clinical Site

    Nantes, France

  • Neurocrine Clinical Site

    Paris, France

  • Neurocrine Clinical Site

    Paris, France

  • Neurocrine Clinical Site

    Dresden, Germany

  • Neurocrine Clinical Site

    Essen, Germany

  • Neurocrine Clinical Site

    Frankfurt, Germany

  • Neurocrine Clinical Site

    Leipzig, Germany

  • Neurocrine Clinical Site

    Munich, Germany

  • Neurocrine Clinical Site

    Athens, Greece

Showing 40 of 70 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.